Horizon Heralds Stellar Launch Of TED Drug Tepezza
One Of The Best New Product Launches In Years
Executive Summary
Despite COVID-19, Horizon Therapeutics has pulled off a spectacularly successful launch of its thyroid eye disease therapy, Tepezza, thanks to pre-commercial activities that led to a high level of initial patient and prescriber awareness, and market access teams securing a decent reimbursement rate.
You may also be interested in...
Finance Watch: CureVac’s IPO Is Ready For Launch
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Horizon Ramps Teprotumumab Launch Plans Into High Gear
With US FDA action on teprotumumab anticipated in March, Horizon has assembled a 100-person commercial team to begin educating physicians and payers on the rare autoimmune condition thyroid eye disease (TED).
Horizon Pharma Sees Mid-2019 BLA For Tepro After Solid Phase III TED Data
Horizon Pharma is on track to file its top pipeline asset for regulatory approval this year after its Phase III confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease met primary and secondary endpoints.
Need a specific report? 1000+ reports available Buy Reports